Paracchi (Assobiotec): Enhance italian biotech thanks to international collaborations

The pandemic has radically changed the vision, the importance and centrality of the biotech sector, this is told by someone who is not a doctor by training but has dealt with finance entrepreneurship and has experienced the biotech and life sciences world before and after the pandemic”, are the words of Pierluigi Paracchi, member of the executive committee of Federchimica – Assobiotec (Italian Association for the Development of Biotechnology), CEO and founder of Genenta Science, a biotechnology company listed on Nasdaq. Paracchi spoke on the topic during the round table entitled “International strategies for emerging biotechnologies and life sciences” at the “Italy – United States of America: international cooperation on emerging biotechnologies and life sciences” event in Rome.

Genenta, listed on the Nasdaq biotech company

The pandemic has changed the world by bringing biotech and life sciences to the center of industrial policies and strategic policies of countries. Governments have noticed this. Genenta is an example because it was born precisely from that excellent Italian scientific research in genetic and cell therapy. Today Genenta deals with oncology and has become a clinical reality that has raised capital in Italy, Europe, Asia and has gained popularity in the United States. From my point of view, the fact that it is the only Italian company listed on the world’s tech market is a biotech is, I hope, the tip of the iceberg of something extraordinary that we have in our country that must be valorised“.

Bilateral USA-Italy: collaboration to improve patients’ lives

In fact, “This bilateral has a fundamental purpose: international collaboration. The pandemic has taught us that we can arrive at solutions very quickly. The fact of being able to have international partnerships has a great impact on the lives of patients.

The conference was the occasion for “the first international public release” of the US National Security Commission on Emerging Biotechnology (NSCEB) and for the US Advanced Research Projects Agency for Health (ARPA-H), “a small Italian pride, the first release on the potential collaboration in such a strategic sector as biotech“.